NCT01038778View on ClinicalTrials.gov

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 29, 2009

Primary Completion Date

May 22, 2019

Study Completion Date

February 12, 2026

Conditions
Clear Cell Renal Cell CarcinomaMetastatic Kidney CarcinomaStage III Renal Cell Cancer AJCC v7Stage IV Renal Cell Cancer AJCC v7
Interventions
BIOLOGICAL

Aldesleukin

Given IV

PROCEDURE

Computed Tomography

Undergo FDG-PET/CT

DRUG

Entinostat

Given PO

RADIATION

Fludeoxyglucose F-18

Undergo FDG-PET/CT

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

PROCEDURE

Positron Emission Tomography

Undergo FDG-PET/CT

Trial Locations (4)

14263

Roswell Park Cancer Institute, Buffalo

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

43210

Ohio State University Comprehensive Cancer Center, Columbus

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH